Dyne: H2 2024 Muscle Disease Data Could Boost Value

Pakin Jarerndee/iStock via Getty Images Dyne Therapeutics, Inc. (NASDAQ:DYN) is advancing the use of its FORCE platform to target skeletal muscle disorders. This would be with the use of modern oligonucleotide technology drugs like DYNE-101 and DYNE-251, which are both being advanced for the treatment of patients with myotonic dystrophy type 1 [DM1] and Duchenne Muscular Dystrophy [DMD] with specific exon skipping mutations. The DYNE-101 candidate is being advanced for the treatment of patients with DM1 in ...